The study, published in the European Journal of Neurology, looked at a single genetic variant—rs7665090—and found that it may predict how well patients respond to interferon-beta (IFNβ) [1], one of the most commonly used MS drugs. And the results were quite unexpected.
A recent study from Singapore has delivered a powerful message: 95% of people may carry at least one gene variant that can impact how they respond to medication. This finding, published in The Pharmacogenomics Journal (2025), is a major milestone in the movement toward personalized, genomics-guided healthcare. It highlights the growing need to make pharmacogenomic (PGx) testing a routine part of primary care.
Pharmacogenomics heralds a revolutionary shift in modern medicine, focusing on tailoring drug therapies to an individual’s genetic profile. This field is revolutionizing healthcare,…
The COVID-19 pandemic has posed unprecedented challenges, prompting a critical inquiry: Might our genetic makeup hold the key to more effective treatments in…
Explore the synergy between PGx and the Microbiome to unlock the secrets of gut health’s role in shaping personalized drug responses.
Explore the complexities of drug resistance genes and their variable impact on phenotypes in our deep dive into genetic influences on treatment outcomes.
Explore the intricate realm of Genomic Mutations, their impacts on health, and advances in detection and management strategies.
Understand the crucial role of non-metabolizing genes and why they should be PGx tested and payor covered.
Explore how GPT-4 & RAG technology are revolutionizing the access to pharmacogenomic data for personalized medicine.
Explore the intersection of multiomics with pharmacogenomics to understand personalized medicine’s future and its impact on healthcare.
End of content
End of content
Join Our Insider’s Circle! Stay up to Date with the latest in PGx